Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction

Neuro-Oncology

Volumn 3, Issue 4, 2001, Pages 229-240

  Riffkin, Christopher D ^a   Gray, Amy Z ^a   Hawkins, Christine J ^a   Chow, C W ^a   Ashley, David M ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; HYBRID PROTEIN; MEMBRANE PROTEIN; TUMOR PROTEIN;

ADOLESCENT; ANIMAL; APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; CHILD; COLORIMETRY; CULTURE MEDIUM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETIC TRANSFECTION; GENETICS; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; HUMAN; INFANT; LEUKEMIA CELL LINE; MALE; MEDULLOBLASTOMA; MOUSE; NEUROBLASTOMA; NEUROECTODERM TUMOR; PATHOLOGY; PHYSIOLOGY; PINEAL BODY; PINEAL BODY TUMOR; PRESCHOOL CHILD;

ADOLESCENT; ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; COLORIMETRY; CULTURE MEDIA, CONDITIONED; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FAS LIGAND PROTEIN; FEMALE; GANGLIOGLIOMA; GERMINOMA; GLIOBLASTOMA; HUMANS; INFANT; JURKAT CELLS; MALE; MEDULLOBLASTOMA; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASM PROTEINS; NEUROBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; PINEAL GLAND; PINEALOMA; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035490840     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-3-4-229     Document Type: Article

References (54)

1. Altman, D.G. (1991) Practical Statistics for Medical Research. London: Chapman and Hall.
2. Armitage, R.J. (1994) Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 6, 407-413.
3. Ashley, D.M., Kong, F.M., Bigner, D.D., and Hale, L.P. (1998) Endogenous expression of transforming growth factor betal inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res. 58, 302-309.
4. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R.C. (1995) A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632.
5. Boldin, M.P., Mett, I.L., Varfolomeev, E.E., Chumakov, I., Shemer-Avni, Y., Camonis, J.H., and Wallach, D. (1995) Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO-1 prompts signaling for TNF and Fas/APO-1 effects. J. Biol. Chem. 270, 387-391.
6. Boldin, M.P., Goncharov, T.M., Goltsev, Y.V., and Wallach, D. (1996) Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 85, 803-815.
7. Cohen, M.E., and Duffner, P.K. (1994) Brain Tumors in Children: Principles of Diagnosis and Treatment. New York: Raven Press.
8. Davidson, W.F., Giese, T., and Fredrickson, T.N. (1998) Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187, 1825-1838.
9. Duke, R.C., Franzusoff, A., and Bellgrau, D. (1996) CD95 ligand in graft rejection. Nature 379, 682-683.
10. Frei, K., Ambar, B., Adachi, N., Yonekawa, Y., and Fontana, A. (1998) Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis. J. Neuroimmunol. 87, 105-113.
11. Gratas, C., Tohma, Y., Barnas, C., Taniere, P., Hainaut, P., and Ohgaki, H. (1998) Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 58, 2057-2062.
12. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., and Ferguson, T.A. (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192.
13. Griffith, T.S., Yu, X., Herndon, J.M., Green, D.R., and Ferguson, T.A. (1996) CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5, 7-16.
14. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., and Tschopp, J. (1996) Melanoma cell expression of Fas (APO-1/CD95) ligand: Implications for tumor immune escape. Science 274, 1363-1366.
15. Hanabuchi, S., Koyanagi, M., Kawasaki, A., Shinohara, N., Matsuzawa, A., Nishimura, Y., Kobayashi, Y., Yonehara, S., Yagita, H., and Okumura, K. (1994) Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 91, 4930-4934.
16. Huang, D.C., Hahne, M., Schroeter, M., Frei, K., Fontana, A., Villunger, A., Newton, K., Tschopp, J., and Strasser, A. (1999) Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proc. Natl. Acad. Sci. U.S.A. 96, 14871-14876.
17. Itoh, N., Tsujimoto, Y., and Nagata, S. (1993) Effect of Bd-2 on Fas antigen-mediated cell death. J. Immunol. 151, 621-627.
18. Itoh, Y., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243.
19. Izumu, I., Mineura, K., Watanabe, K., and Kowada, M. (1993) Characterization and chemosensitivity of two cell lines derived from human glioblastomas. J. Neurooncol. 17, 111-121.
20. Kawai, K., Serizawa, A., Hamana, T., and Tsutsumi, Y. (1994) Heat-induced antigen retrieval of proliferating cell nuclear antigen and p53 protein in formalin-fixed, paraffin-embedded sections. Pathol. Int. 44, 759-764.
21. Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., and Yagita, H. (1995) Metaloprotease-mediated release of human Fas ligand. J. Exp. Med. 182, 1777-1783.
22. Kayagaki, N., Yamaguchi, N., Nagao, F., Matsuo, S., Maeda, H., Okumura, K., and Yagita, H. (1997) Polymorphism of murine Fas ligand that affects the biological activity. Proc. Natl. Acad. Sci. U.S.A. 94, 3914-3919.
23. Kischkel, F.C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P.H., and Peter, M.E. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588.
24. Leithauser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Bruderlein, S., Henne, C., Schmidt, A., Debatin, K.M., Krammer, P.H., and Moller, P. (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69, 415-429.
25. Medema, J.P., Scaffidi, C., Kischkel, F.C., Shevchenko, A., Mann, M., Krammer, P.H., and Peter, M.E. (1997) FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794-2804.
26. Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E., and Dixit, V.M. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827.
27. Nagata, S., and Golstein, P. (1995) The Fas death factor. Science 267, 1449-1456.
28. O'Connell, J., O'Sullivan, G.C., Collins, J.K., and Shanahan, F. (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082.
29. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B.C., Ponsting, H., and Krammer, P.H. (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with Fas antigen. J. Biochem. 267, 10709-10715.
30. Oshimi, Y., Oda, S., Honda, Y., Nagata, S., and Miyazaki S. (1996) Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J. Immunol. 157, 2909-2915.
31. Rensing-Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S.M., Weller, M., Aebischer, P., Krammer, P.H., and Fontana, A. (1995) Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25, 2253-2258.
32. Rensing-Ehl, A., Malipiero, U., Irmler, M., Tschopp, J., Constam, D., and Fontana, A. (1996) Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway. Eur. J. Immunol. 26, 2271-2274.
33. Saas, P., Boucraut, J., Quiquerez, A.L., Schnuriger, V., Perrin, G., Desplat-Jego, S., Bernard, D., Walker, P.R., and Dietrich, P.Y. (1999) CD95 (Fas/APO-1) as a receptor governing astrocyte apoptotic or inflammatory responses: A key role in brain inflammation? J. Immunol. 162, 2326-2333.
34. Saas, P., Walker, P.R., Hahne, M., Quiquerez, A.L., Schnuriger, V., Perrin, G., French, L., Van Meir, E.V., de Tribolet, N.D., Tschopp, J., and Dietrich, P.Y. (1997) Fas ligand expression by astrocytoma in vivo: Maintaining immune privlege in the brain? J. Clin. Invest. 99, 1173-1178.
35. Scaffidi, C., Fulda, S., Srinivasen, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., and Peter, M.E. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687.
36. Schneider, P., Holler, N., Bodmer, J.L., Hahne, M., Frei, K., Fontana, A., and Tschopp, J. (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 18, 1205-1213.
37. Singer, G.G., Carrera, A.C., Marshak-Rothstein, A., Martinez, C., and Abbas, A.K. (1994) Apoptosis, Fas and systemic autoimmunity: The MRL-lpr/lpr model. Curr. Opin. Immunol. 6, 913-920.
38. Strand, S., Hofmann, W.J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S.M., Stremmel, W., Krammer, P.H., and Galle, P.R. (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells -a mechanism of immune invasion? Nat. Med. 2, 1361-1366.
39. Strasser, A., and Newton, K. (1999) FADD/MORT1, a signal transducer that can promote cell death or cell growth. Int. J. Biochem. Cell Biol. 31, 533-537.
40. Suda, T., Takahashi, T., Goldstein, P., and Nagata, S. (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178.
41. Tachibana, O., Nakazawa, H., Lampe, J., Watanabe, K., Kleihues, P., and Ohgaki, H. (1995) Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 55, 5528-5530.
42. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. (1995) Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135.
43. Tohma, Y., Gratas, C., Van Meir, E.G., Desbaillets, I., Tenan, M., Tachibana, O., Kleihues, P., and Ohgaki, H. (1998) Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57, 239-245.
44. Tounekti, O., Belehradek, J., Jr., and Mir, L.M. (1995) Relationships between DNA fragmentation, chromatin condensation, and changes in flow cytometry profiles detected during apoptosis. Exp. Cell Res. 217, 506-516.
45. Trauth, B.C., Klas, C., Peters, A.M., Matzku, S., Moller, P., Falk, W., Debatin, K.M., and Krammer, P.H. (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305.
46. Walker, P.R., Saas, P., and Dietrich, P.Y. (1997) Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back. J. Immunol. 158, 4521-4524.
47. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., and Nagata, S. (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317.
48. Weller, M., Frei, K., Groscurth, P., Krammer, P.H., Yonekawa, Y., and Fontana, A. (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94, 954-964.
49. Weller, M., Malipiero, U., Aguzzi, A., Reed, J.C., and Fontana, A. (1995a) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest 95, 2633-2643.
50. Weller, M., Malipiero, U., Rensing-Ehl, A., Barr, P.J., and Fontana, A. (1995b) Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55, 2936-2944.
51. Weller, M., Schuster, M., Pietsch, T., and Schabet, M. (1998) CD95 ligand-induced apoptosis of human medulloblastoma cells. Cancer Lett. 128, 121-126.
52. Werner, M., Von Wasielewski, R., and Komminoth, P. (1996) Antigen retrieval, signal amplification and intensification in immunohistochemistry. Histochem. Cell Biol. 105, 253-260.
53. Yagita, H., Seino, K., Kayagaki, N., and Okumura, K. (1996) CD95 ligand in graft rejection. Nature 379, 682.
54. Yonehara, S., Ishii, A., and Yonehara, M. (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169, 1747-1756.